On October 15, 2026, Madison Square Garden Sports Corp (NYSE: MSGS) announced it is on track to complete the spinoff of the New York Rangers hockey franchise on October 26, resulting in two separately traded companies. This strategic separation will split the basketball and hockey operations into independent entities, pending NBA and NHL approvals.
GF Value™ indicates MSGS is significantly overvalued, with the current stock price of $404.10 trading approximately 72.1% above its intrinsic value estimate of $234.79. GF Score™ stands at 49/100, reflecting a mixed profile with moderate financial strength and profitability but weak growth and valuation metrics. Insider activity shows net selling over the past 12 months, with no insider purchases and $2.1 million in shares sold, signaling cautious insider sentiment despite stable institutional ownership.What’s Behind the News?
The upcoming spinoff will divide Madison Square Garden Sports into two publicly traded companies: MSG Knickerbockers Corp., which will retain ownership of the New York Knicks basketball team and its G League affiliate, and MSG Rangers Corp., which will oversee the New York Rangers hockey team and its AHL affiliate. Both entities will trade under new tickers—MSGK for the Knicks and MSGR for the Rangers. James Dolan will continue as executive chairman and CEO of both companies, ensuring leadership continuity.
Madison Square Garden Sports Corp currently operates as a professional sports holding company primarily focused on the New York Knicks (NBA) and New York Rangers (NHL), along with their respective minor league affiliates and related ventures such as merchandise and training centers. The company is listed on the NYSE with a market capitalization of $9.73 billion, classified under the Communication Services sector and Media – Diversified industry. Its revenue streams are diversified across ticket sales, premium seating, media rights, sponsorships, merchandise licensing, and concessions, capitalizing on the large New York metropolitan sports market.
Is MSGS Overvalued or Undervalued?
According to GuruFocus’ proprietary GF Value™ metric, MSGS is trading at $404.10 per share, which is 72.1% above its intrinsic value estimate of $234.79. This substantial premium suggests a limited margin of safety for new investors, indicating the stock is significantly overvalued at current levels. The GF Value™ calculation integrates historical trading multiples, business growth trends, and forward-looking performance estimates to derive a comprehensive intrinsic valuation.
The valuation concern is further underscored by the trailing twelve months (TTM) price-to-earnings (P/E) ratio of 1,299.36x, which is dramatically higher than the five-year median P/E of 85.09x. This extreme divergence reflects either market optimism priced into the stock or underlying earnings volatility and decline, as the company’s earnings growth has been stagnant or negative in recent years. The forward P/E ratio is effectively non-existent due to expected earnings declines, reinforcing the valuation risk. Investors can explore more about GF Value™ and its methodology here.
What Does MSGS’s GF Score™ Tell Us?
The GF Score™ is a composite measure designed to evaluate a company’s overall quality by assessing financial strength, profitability, growth, valuation, and momentum. MSGS’s GF Score™ of 49/100 indicates a middling profile, with some areas of strength but notable weaknesses that investors should consider.
Metric Rating GF Score™ 49/100 Financial Strength 4/10 Profitability 5/10 Growth 2/10 Valuation 1/10 Momentum 3/10
MSGS demonstrates moderate profitability and financial strength but struggles with growth and valuation metrics, which drag down the overall GF Score™. The low valuation rank of 1/10 aligns with the significant overvaluation indicated by GF Value™ and P/E ratios. Growth is particularly weak, with a rank of 2/10, reflecting stagnant earnings and EBITDA declines over recent years. Momentum is also subdued, suggesting limited positive price movement catalysts. For a detailed breakdown, visit the MSGS stock page.
What Are Gurus and Insiders Doing with MSGS?
Institutional guru ownership remains robust, with 10 premium gurus holding MSGS shares. Interestingly, the recent activity shows a balanced approach, as 5 gurus have increased their positions while another 5 have trimmed holdings in recent quarters. This mixed guru activity reflects a cautious stance amid valuation concerns and corporate restructuring. Meanwhile, insider transactions reveal no insider buying over the past 12 months but $2.1 million worth of insider selling, including 628 shares sold in the last 3 months. This insider selling may indicate a lack of confidence in near-term upside despite stable institutional interest.
What This Means for Investors
The imminent spinoff of MSGS into two distinct entities presents a significant corporate restructuring event, but from a valuation standpoint, MSGS currently trades at a steep premium to its intrinsic GF Value™. The wide margin of overvaluation, coupled with a very high P/E ratio relative to historical norms and weak growth metrics, suggests investors should approach the stock with caution. The mixed signals from institutional gurus—some adding, some trimming—and insider selling further complicate the outlook. Investors seeking exposure to MSGS should weigh the potential benefits of the spinoff against the elevated valuation risks. For those interested in monitoring MSGS’s evolving fundamentals and market performance, the MSGS stock page offers comprehensive data and updates.
Frequently Asked Questions
What is MSGS’s GF Score™?
MSGS’s GF Score™ is 49 out of 100, indicating a moderate overall quality with strengths in profitability and financial health but weaknesses in growth and valuation.
Is MSGS overvalued or undervalued?
MSGS is significantly overvalued, trading approximately 72.1% above its GF Value™ of $234.79, suggesting limited margin of safety for investors.
What is MSGS’s P/E ratio compared to historical?
The trailing twelve months P/E ratio of MSGS is 1,299.36x, vastly exceeding its five-year median P/E of 85.09x, highlighting an extreme valuation premium relative to historical levels.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].